Abeona Therapeutics (NASDAQ:ABEO) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO – Get Rating) in a note issued to investors on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Abeona Therapeutics Stock Up 0.8 %

NASDAQ:ABEO opened at $2.62 on Thursday. Abeona Therapeutics has a 52-week low of $2.19 and a 52-week high of $9.35. The firm has a market cap of $45.01 million, a P/E ratio of -0.14 and a beta of 1.20. The business’s 50-day moving average price is $2.61 and its 200 day moving average price is $3.29.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ABEO. Citigroup Inc. acquired a new position in shares of Abeona Therapeutics in the 1st quarter valued at $27,000. Creative Planning acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at $62,000. State Street Corp boosted its position in shares of Abeona Therapeutics by 24.6% in the 2nd quarter. State Street Corp now owns 377,402 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 74,600 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $103,000. Finally, Jane Street Group LLC acquired a new stake in Abeona Therapeutics during the 4th quarter worth about $115,000. Institutional investors and hedge funds own 37.69% of the company’s stock.

About Abeona Therapeutics

(Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.